Welcome GeneTx, it's refreshing to have someone of your knowledge in the clinical space on board, particularly someone from the US working in a top medical institution - and similar public listed company. We've all been wondering is the message making its way across the pacific, but it also confirms that the investors usually have an interest in clinical trials, a interest in science and an ability to distill data and do their own research. Hence why the investor pool is niche and not everyones cup of tea. Heck, most of us who have tried to discuss IMU with friends, family or co workers will have seen their interest/attention wain!
Anyway, great to hear from you, you offer us a fantastic perspective.
cheers.
IMU Price at posting:
5.7¢ Sentiment: Buy Disclosure: Held
(20min delay)